Please assess the completion status of the following clinical trial:

Trial Title: A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have postmenopausal status.~* Adenocarcinoma of the breast.~* Breast tumor ≥1 centimeter (cm) in diameter, HR+, HER2-.~* Neoadjuvant endocrine monotherapy is deemed to be a suitable therapy.~* Primary breast cancer that is suitable for baseline core biopsy.~* Have adequate organ function.~Exclusion Criteria:~* Bilateral invasive breast cancer.~* Metastatic breast cancer (local spread to axillary lymph nodes is permitted).~* Inflammatory breast cancer.~* Prior systemic therapy or radiotherapy for invasive or non-invasive breast cancer in the same breast as currently being treated.~* Prior radiotherapy to the ipsilateral chest wall for any malignancy.~* Prior anti-estrogen therapy.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abemaciclib + Anastrozole (Type: EXPERIMENTAL): Abemaciclib (150 milligrams \[mg\]) was given orally every 12 hours (Q12H) plus anastrozole (1 mg) orally once daily (QD) for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion.~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Total treatment duration was 16 weeks.
- Abemaciclib (Type: EXPERIMENTAL): Abemaciclib (150 mg) was given orally Q12H for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion.~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Total treatment duration was 16 weeks.
- Anastrozole (Type: ACTIVE_COMPARATOR): Anastrozole (1 mg) is given orally QD for 2 weeks.~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Loperamide was given as a prophylaxis for the first 2 weeks of the combination treatment and then at physician discretion. Total treatment duration was 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).